Hales Craig M, Ogden Cynthia L, Freedman David S, Sahu Kushal, Hale Paula M, Mamadi Rashmi K, Kelly Aaron S
Centers for Disease Control and Prevention, Hyattsville, MD, USA.
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Child Obes. 2025 Jan;21(1):22-29. doi: 10.1089/chi.2024.0248. Epub 2024 Jul 12.
The BMI z-score is a standardized measure of weight status and weight change in children and adolescents. BMI z-scores from various growth references are often considered comparable, and differences among them are underappreciated. This study reanalyzed data from a weight management clinical study of liraglutide in pubertal adolescents with obesity using growth references from CDC 2000, CDC Extended, World Health Organization (WHO), and International Obesity Task Force. BMI z-score treatment differences varied 2-fold from -0.13 (CDC 2000) to -0.26 (WHO) overall and varied almost 4-fold from -0.05 (CDC 2000) to -0.19 (WHO) among adolescents with high baseline BMI z-score. Depending upon the growth reference used, BMI z-score endpoints can produce highly variable treatment estimates and alter interpretations of clinical meaningfulness. BMI z-scores cited without the associated growth reference cannot be accurately interpreted.
BMI z评分是衡量儿童和青少年体重状况及体重变化的标准化指标。来自各种生长参考标准的BMI z评分通常被认为具有可比性,但其之间的差异却未得到充分重视。本研究使用美国疾病控制与预防中心(CDC)2000版、CDC扩展版、世界卫生组织(WHO)以及国际肥胖特别工作组的生长参考标准,重新分析了一项关于利拉鲁肽治疗青春期肥胖青少年体重管理的临床研究数据。总体而言,BMI z评分的治疗差异在-0.13(CDC 2000)至-0.26(WHO)之间有2倍的变化,而在基线BMI z评分较高的青少年中,差异从-0.05(CDC 2000)至-0.19(WHO)几乎有4倍的变化。根据所使用的生长参考标准不同,BMI z评分终点可产生高度可变的治疗评估结果,并改变对临床意义的解读。未提及相关生长参考标准的BMI z评分无法得到准确解读。